e-Therapeutics announces appointment of Steve Medlicott as Finance Director

22 April 2014
etherapeutics-original-logo

UK-based drug discovery and development company e-Therapeutics (AIM: ETX) has announced the appointment of Steve Medlicott as Finance Director.

Mr Medlicott joins e-Therapeutics’ management team having previously advised the Company in its £40m fundraising in 2013.

Mr Medlicott held key business development and sell-side analyst roles with Peel Hunt, N+1 Singer, Altium Capital and Williams de Broe. He was voted the top Industrials analyst in the Thomson Reuters Extel survey numerous times, and was the top Pan-European Industrials analyst in the 2011 Reuters Starmine Awards. He co-founded Blueprint Advisors in 2012.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical